ASX Healthcare Stocks - Stocks Down Under

A Blood Test Instead of a Colonoscopy? Rhythm Biosciences (ASX:RHY) Takes Its First Commercial Step

Rhythm Biosciences Starts ColoSTAT Pilot, Revenue Still Unclear Rhythm Biosciences (ASX: RHY) just hit a milestone the market has been waiting for, enrolling its first doctor in the ColoSTAT Access…

Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the…

Island Pharmaceuticals (ASX:ILA) Raises A$9M as FDA Confirms Galidesivir Pathway: Is This Small-Cap Biotech a Buy?

Island Pharmaceuticals jumps after FDA backs galidesivir pathway Island Pharmaceuticals (ASX: ILA) surged as much as 23% to an intraday high of A$0.48 on Wednesday before settling at A$0.42, after…

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals: Is the 10% drop a buy signal? Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to A$14.63 from a previous close of A$16.25. The sell-off came…

Is it Time to Buy ResMed (ASX:RMD)? It is Crushing the Ozempic Fear Narrative with New Data!

ResMed data shows GLP-1 users use CPAP more Is it time to buy ResMed (ASX: RMD)? Well, the company is having good momentum right now - it delivered another strong…

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

Telix Pharmaceuticals Shares Slide After Regulatory Setbacks Telix Pharmaceuticals (ASX: TLX) has had a brutal twelve months. Shares have fallen around 63% from their February 2025 all-time high of A$31.97…

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Aroa Biosurgery adds new trauma study as profits turn positive Aroa Biosurgery (ASX: ARX) shares have seen increased activity this week, hovering around the A$0.70 level following news that…

Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?

Anteris Technologies Gains Momentum with Medtronic Partnership Anteris Technologies (ASX: AVR) jumped more than 30% after announcing a deal that could change its future. The Australian heart valve company secured…

Osteopore (ASX:OSX) Secures A$2.6M China Deal: Micro-Cap Opportunity or Too Risky to Buy?

Osteopore signs a major China distribution deal, but risks remain Osteopore (ASX: OSX) surged 71 per cent last Friday after announcing an exclusive distribution deal with Majeton Limited valued at…

Proteomics International (ASX:PIQ) Appoints New CEO as US Sales Push Begins: Is It Time to Buy?

Proteomics International begins its US sales push as Medicare reimbursement starts At Proteomics International (ASX: PIQ), new CEO David Morris takes the reins today as the Perth-based medical technology company shifts…